Open-house pharmaceutical rebate agreements for testosterone, excluding the injectable solution dosage form, ATC G03BA03

Summary

This is an open-house arrangement for non-exclusive pharmaceutical rebate agreements concerning testosterone, excluding the injectable solution dosage form (ATC G03BA03). The contracting authority intends to conclude identical, non-negotiable agreements with every interested pharmaceutical company that meets the requirements; there is no competitive selection between bidders. The earliest possible contract start date is 1 November 2026 and all agreements end on 31 October 2028. A company may join during the term, but no later than 3 September 2028. Complete and correct documents received by the 3rd day of a month generally allow the agreement to start on the first day of the following month. The agreement may be terminated with one month’s notice to the end of a calendar month. Companies should verify the required forms, submission procedure and confidentiality obligations in the official tender documents.